Executive Management

Xiaodong Wang, Ph.D., Founder & Chairman SAB

Xiaodong Wang, Ph.D.

Founder & Chairman, Scientific Advisory Board

  • Founded BeiGene in 2010, and has served as Chairman of Scientific Advisory Board since 2011
  • Founding Director & Architect of 700-person team at the National Institute of Biological Sciences (NIBS) in Beijing (2003-present)
  • Howard Hughes Medical Institute Investigator, George L. MacGregor Distinguished Chair in Biomedical Sciences (1997-2010) and Professor in Biomedical Sciences (2001-2010) at University of Texas Southwestern Medical Center
  • Member of National Academy of Sciences, USA
  • Foreign associate of Chinese Academy of Sciences
  • Founder of Joyant Pharmaceuticals, venture capital-backed oncology biotech in US
  • Ph.D. in Biochemistry from University of Texas Southwestern Medical Center
  • B.S. in Biology from Beijing Normal University
John V. Oyler, Founder & CEO

John V. Oyler

Founder & CEO

  • Has served as CEO and Director since founding BeiGene in 2010
  • Founder & CEO of BioDuro, 700-person integrated research CRO in Beijing, sold to Pharmaceutical Product Development Inc. with attractive returns (2005-2009)
  • CEO of Galenea, Boston biotech started from MIT with funding from Otsuka, (2002-2004)
  • Founder, President of Telephia, sold to Nielsen (1997-2002)
  • Co-CEO of Genta (GNTA), publicly-traded oncology company that grew in late ’90s to $1.7 billion in revenues (1997-1998)
  • Began career at McKinsey & Company
  • MBA from Stanford University
  • B.S. from Massachusetts Institute of Technology
Howard Liang, Ph.D., CFO and Chief Strategy Officer

Howard Liang, Ph.D.

CFO and Chief Strategy Officer

  • Former Managing Director and Head of Biotechnology Equity Research at Leerink Partners
  • Institutional Investor All-America Research Team, Biotechnology / Mid- & Small-Cap, 2015; Bloomberg Markets Top US Analysts in Biotechnology, 2012; Wall Street Journal “Best of the Street” in Biotechnology and Pharmaceuticals, 2010 and in Biotechnology, 2008
  • Senior biotechnology analyst at AG Edwards, JMP Securities; Associate Analyst at Prudential Securities covering major and specialty pharmaceuticals
  • Senior Scientist at Abbott Laboratories and member of industry’s leading structure-based drug design teams; authored review and 13 papers including six in Nature, Science, and Proceedings of National Academy of Sciences
  • M.B.A., and Ph.D. in Biochemistry and Molecular Biology from The University of Chicago
  • B.S. in Chemistry from Peking University
headshot_amypeterson3

Amy Peterson, M.D

Chief Medical Officer, Immuno-oncology

  • Former Vice President of Clinical Development at Medivation
  • Former Associate Group Medical Director at Genentech
  • Former Instructor of Medicine in Oncology at the University of Chicago
  • Former residency in Internal Medicine at Northwestern Memorial Hospital and Fellowship in Hematology and Oncology at the University of Chicago
  • M.D. from Thomas Jefferson University in Philadelphia, PA
  • Bachelor of Arts from Wesleyan University in Middletown, CT
Jane Huang-01 (2)

Jane Huang, M.D.

Chief Medical Officer, Hematology

  • Former Vice President and Head of Clinical Development at Acerta Pharma (a subsidiary of Astra Zeneca)
  • Former Group Medical Director, Product Development-Oncology at Genentech (a Member of the Roche Group)
  • Adjunct Clinical Faculty and Attending in Thoracic Oncology at Stanford University
  • Board Certified in Hematology, Oncology, and Internal Medicine
  • Fellowship in Hematology and Oncology and Residency in Internal Medicine at Stanford University
  • M.D. from University of Washington School of Medicine
  • Bachelor of Science degree with Honors in Biological Sciences from Stanford University
Eric Hedrick (2)

Eric Hedrick, M.D.

Clinical advisor

  • Former Chief Medical Officer at Epizyme
  • VP of Oncology Development at Pharmacyclics
  • Group Medical Director at Genentech
  • Attending Physician in Hematology Service at Memorial Sloan-Kettering Cancer Center
  • M.D. from University of Maryland School of Medicine
Ji Li

Ji Li, Ph.D.

Global Head of Business Development

  • More than 18 years of Business Development and R&D experience in biopharma industry
  • Former member of the Board of Directors of BeiGene, as a representative for Merck, up until BeiGene’s IPO in February 2016
  • Former Vice President of Business Development and Licensing at Merck & Co. Inc
  • Former Executive Licensing Director, External R&D at Amgen
  • Key member of Amgen research team discovered and validated the RANKL signaling pathway that has led to the development of Denosumab, the current standard of care therapy for osteoporosis, cancer bone metastasis and other bone loss indications.
  • Ph.D. in Neuroscience from Mount Sinai School of Medicine in New York
  • B.S. in Pharmacology from Shanghai Medical University